Gilead Sciences beats by $0.05, beats on revs; sees FY14 net product sales of $11.3-11.5 bln
Reports Q4 (Dec) earnings of $0.55 per share, $0.05 better than the Capital IQ Consensus Estimate of $0.50; revenues rose 20.5% year/year to $3.12 bln vs the $2.84 bln consensus.
Atripla sales +1.8% yoy to $933.6 mln
Truvada sales -2.2% yoy to $814.1 mln
Antiviral product sales increased 22 percent to $2.64 billion for the fourth quarter of 2013, compared to $2.17 billion for the fourth quarter of 2012, reflecting sales growth of 30 percent in the U.S. and 7 percent in Europe.
Cardiovascular product sales increased 25 percent to $268.5 million for the fourth quarter of 2013 compared to the same period in 2012.
Co sees FY14 net product sales of $11.3-11.5 bln, non-GAAP product gross margin of 75-77%, and "Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses" of $0.63-0.66.